Stockscreener 앱 받기
27.75
1.80%
-0.51
전일 마감가:
$28.26
열려 있는:
$28.6
하루 거래량:
413.25K
Relative Volume:
1.18
시가총액:
$1.61B
수익:
-
순이익/손실:
$-118.12M
주가수익비율:
-12.17
EPS:
-2.2802
순현금흐름:
$-82.63M
1주 성능:
+3.85%
1개월 성능:
+4.21%
6개월 성능:
+43.56%
1년 성능:
+49.43%
1일 변동 폭
$27.63
$29.05
1주일 범위
$25.91
$29.05
52주 변동 폭
$16.00
$30.68
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
27.75 | 1.61B | 0 | -118.12M | -82.63M | -2.2802 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-19 | 개시 | JP Morgan | Overweight |
| 2025-08-27 | 개시 | Needham | Buy |
| 2023-12-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-10-05 | 개시 | Stifel | Buy |
| 2023-06-14 | 개시 | BofA Securities | Buy |
| 2023-06-12 | 개시 | H.C. Wainwright | Buy |
| 2023-06-08 | 개시 | Robert W. Baird | Outperform |
| 2023-05-10 | 개시 | Pareto | Buy |
| 2023-04-28 | 개시 | Wedbush | Outperform |
모두보기
Oculis Holding Ag 주식(OCS)의 최신 뉴스
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting - GlobeNewswire
Oculis Nears Key Milestone as Phase 3 OCS-01 Eye Drop Trial in Diabetic Macular Edema Completes - TipRanks
H.C. Wainwright raises Oculis stock price target to $44 on trial progress - Investing.com
Gildi lifeyrissjodur Makes New Investment in Oculis Holding AG $OCS - MarketBeat
Oculis Highlights Innovative Late-Stage Pipeline and Unmet Needs in Diabetic Macular Edema at ARVO 2026 - Quiver Quantitative
June eye-drop data nears as Oculis brings DME, optic neuritis studies - Stock Titan
OCSAW Price History for Oculis Holding Ag Warrants Stock - Barchart.com
Oculis (NASDAQ:OCS) Sees Strong Trading VolumeWhat's Next? - MarketBeat
OCSAW Chart for Oculis Holding Ag Warrants Stock - Barchart.com
LSP 7 holds 6.95M shares in Oculis Holding (OCS) as of Mar 31, 2026 - Stock Titan
Should Oculis Completing Phase 3 Trials for Topical DME Drug OCS-01 Require Action From OCS Investors? - Yahoo Finance
Oculis reports final phase 3 patient visit for DME eye drops - Eyes On Eyecare
Assessing Oculis Holding (OCS) Valuation As DIAMOND Phase 3 Trials Reach Key Completion Milestone - simplywall.st
Oculis Advances Targeted Dry Eye Drug Licaminlimab Into Late-Stage Testing - TipRanks
(OCS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Oculis Sets May 13, 2026 AGM in Zug and Schedules Shareholder Info Session - TipRanks
Oculis (Nasdaq: OCS) sets 2026 AGM, details late-stage pipeline and expanded share capital tools - Stock Titan
Oculis Publishes Invitation to the Annual General Meeting - GlobeNewswire
Oculis (NASDAQ:OCS) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Oculis Holding AG (NASDAQ:OCS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
H.C. Wainwright reiterates Oculis stock rating on trial completion By Investing.com - Investing.com Australia
Why Oculis Holding (OCS) Is Up 5.5% After Phase 3 DME Trial Milestone – And What's Next - simplywall.st
OCS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $44 - GuruFocus
Oculis completes final patient visit in OCS-01 phase 3 trial in DME - Ophthalmology Times
HC Wainwright Reiterates Buy Rating for Oculis (NASDAQ:OCS) - MarketBeat
Oculis Holding AG Announces Completion of Last Patient Visit in Phase 3 Diamond Program with OCS-01 Eye Drops for Treatment of Diabetic Macular Edema - marketscreener.com
Oculis Completes Last Patient Visits in Phase 3 DIAMOND Trials for OCS-01, Anticipates Topline Results in June 2026 - Quiver Quantitative
800+ patients finish Oculis diabetic eye-drop trials before June data - Stock Titan
Oculis Announces Completion of Last Patient Visit in Phase - GlobeNewswire
Oculis Holding AG (OCS) Stock Analysis: A Promising Biotech with a 74.79% Potential Upside - DirectorsTalk Interviews
Liquidity Mapping Around (OCS) Price Events - Stock Traders Daily
Tech Rally: Will Oculis Holding AG Equity Warrant benefit from green energy policiesMarket Sentiment Summary & Risk Managed Investment Signals - baoquankhu1.vn
Surprises Report: Is Oculis Holding AG Equity Warrant exposed to political riskPortfolio Risk Summary & Proven Capital Preservation Methods - baoquankhu1.vn
Is Oculis (OCSAW) Stock heavily shorted | Price at $15.99, Up 0.60%Global Trading Community - Cổng thông tin điện tử tỉnh Lào Cai
OCS Options Volatility — NASDAQ:OCS - TradingView
OCS Options Chain — NASDAQ:OCS - TradingView
Value Recap: Will Oculis Holding AG Equity Warrant benefit from green energy policiesWeekly Profit Recap & Daily Profit Focused Stock Screening - baoquankhu1.vn
Fund Flows: Whats next for Oculis Holding AG stockShare Buyback & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Can Oculis (OCS) Stock Recover Now | Price at $27.39, Up 0.74%RSI Oversold Stocks - Cổng thông tin điện tử tỉnh Lào Cai
OCS Stock Price, Quote & Chart | OCULIS HOLDING AG (NASDAQ:OCS) - ChartMill
Director Riad Sherif's Oculis RSUs vested and settled on April 5 - Stock Titan
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - marketscreener.com
Will Oculis (OCS) Stock Go Higher | Price at $27.00, Up 2.27%Buy Zone Stocks - Xã Thanh Hà
Oculis Holding AG (OCSAW) Stock Price, News, Quote & History - Yahoo! Finance Canada
Oculis Announces 2026 Investor Conference Participation and Key Updates - Intellectia AI
Oculis to Participate in Upcoming Investor Conferences - Bitget
Oculis Holding AG Announces Upcoming Investor Conferences and Pipeline Updates for 2026 Progress - Quiver Quantitative
Investment Report: Can Oculis Holding AG Equity Warrant stock double in the next yearPortfolio Risk Summary & Capital Efficient Trade Techniques - baoquankhu1.vn
Assessing Oculis Holding (OCS) Valuation After EMA PRIME Designation For Privosegtor - Sahm
Oculis Holding (OCS) Is Up 7.9% After EMA PRIME Tag For Optic Neuritis Drug Candidate - Sahm
Risk Check: Is Oculis Holding AG Equity Warrant benefiting from interest rate changes2026 Trends & Verified Chart Pattern Signals - baoquankhu1.vn
Oculis Holding Ag (OCS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):